Top

BMC Medical Genetics

Published in:

Open Access 01-12-2014 | Technical advance

Detection of allele specific differences in IFNL3 (IL28B)mRNA expression

Authors: Susanne Knapp, Naeem Meghjee, Sorcha Cassidy, Khaleel Jamil, Mark Thursz

Published in: BMC Medical Genetics | Issue 1/2014

Abstract

Background

Variants of the interferon-lambda3 (IFNL3) gene have been associated with both spontaneous and treatment induced clearance of HCV infection. Attempts to link polymorphisms of the IFNL3 gene with variation in the level of IFNL3 expression have been inconclusive. This is partially due to the difficulty to design assays distinguishing IFNL3 from IFNL2.

Methods

In this study an allele specific real-time PCR (RT-PCR) assay was developed which allows the relative quantification of the two IFNL3 transcripts in cells heterozygous for SNP IFNL3.rs4803217 in the 3'UTR of the IFNL3 gene. This SNP is in strong linkage disequilibrium (LD) with the predictive marker rs12979860.

Results

Raji cells showed two-fold increased levels of IFNL3.rs4803217 C-allele expression. In peripheral blood mononuclear cells (PBMCs) of eight uninfected donors, two donors showed increased IFNL3.rs4803217 C-allele expression.

Conclusion

This indicates that allele specific differences in IFNL3 expression vary between individuals and might contribute to the variety of outcomes in HCV infected patients.

Available only for authorised users

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009, 461 (7262): 399-401. 10.1038/nature08309.CrossRefPubMed

Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009, 461 (7265): 798-801. 10.1038/nature08463.CrossRefPubMedPubMedCentral

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009, 41 (10): 1105-9. 10.1038/ng.449.CrossRefPubMed

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009, 41 (10): 1100-4. 10.1038/ng.447.CrossRefPubMed

Rauch A, Kutalik Z, Descombes P, Cai T, Di IJ, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY: Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010, 138 (4): 1338-45. 10.1053/j.gastro.2009.12.056. 1345CrossRefPubMed

Pedergnana V, Abdel-Hamid M, Guergnon J, Mohsen A, Le Fouler L, Theodorou I, Mohamed MK, Fontanet A, Plancoulaine S, Abel L: Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of hepatitis C virus. PLoS One. 2012, 7 (6): e38578-10.1371/journal.pone.0038578.CrossRefPubMedPubMedCentral

Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, Takahashi S, Kubo M, Nakamura Y, Chayama K, Mitsui F, Hiraga N, Imamura M, Takahashi S, Kubo M, Nakamura Y, Chayama K: IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol. 2011, 54 (6): 1094-101. 10.1016/j.jhep.2010.09.019.CrossRefPubMed

Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N: IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010, 52 (6): 1888-96. 10.1002/hep.23912.CrossRefPubMedPubMedCentral

Ito K, Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H, Aoki Y, Sato Y, Imamura M, Murata K, Nomura H, Hige S, Adachi H, Hino K, Yatsuhashi H, Orito E, Kani S, Tanaka Y, Mizokami M: The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011, 49 (5): 1853-60. 10.1128/JCM.02139-10.CrossRefPubMedPubMedCentral

10.

Sugiyama M, Kimura T, Naito S, Mukaide M, Shinauchi T, Ueno M, Ito K, Murata K, Mizokami M: Development of specific and quantitative real-time detection PCR and immunoassays for λ3-interferon. Hepatol Res. 2012, 42 (11): 1089-99. 10.1111/j.1872-034X.2012.01032.x. doi:10.1111/j.1872-034X.2012.01032.x. Epub 2012 Jun 5CrossRefPubMed

11.

De Castellarnau M, Aparicio E, Parera M, Franco S, Tural C, Clotet B, Martinez MA: Deciphering the interleukin 28B variants that better predict response to pegylated interferon-alpha and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS One. 2012, 7 (2): e31016-10.1371/journal.pone.0031016.CrossRefPubMedPubMedCentral

12.

Smith KR, Suppiah V, O'Connor K, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Matthews G, Irving WL, Powell E, Riordan S, Ahlenstiel G, Stewart GJ, Bahlo M, George J, Booth DR: International Hepatitis C Genetics Consortium (IHCGC): Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med. 2011, 3 (8): 57-10.1186/gm273.CrossRefPubMedPubMedCentral

13.

Germer S, Holland MJ, Higuchi R: High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR. Genome Res. 2000, 10 (2): 258-66. 10.1101/gr.10.2.258.CrossRefPubMedPubMedCentral

14.

Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J: Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 1982, 42 (9): 3858-63.PubMed

15.

Drexler HG, Minowada J: History and classification of human leukemia-lymphoma cell lines. Leuk Lymphoma. 1998, 31 (3'4): 305-16.CrossRefPubMed

16.

Schneider U, Schwenk HU, Bornkamm G: Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer. 1977, 19 (5): 621-6. 10.1002/ijc.2910190505.CrossRefPubMed

17.

Zhao LJ, Hua X, He SF, Ren H, Qi ZT: Interferon alpha regulates MAPK and STAT1 pathways in human hepatoma cells. Virol J. 2011, 8: 157-10.1186/1743-422X-8-157.CrossRefPubMedPubMedCentral

18.

Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M: Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature. 2007, 449 (7164): 919-22. 10.1038/nature06205.CrossRefPubMedPubMedCentral

19.

Shin EC, Seifert U, Kato T, Rice CM, Feinstone SM, Kloetzel PM, Rehermann B: Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest. 2006, 116 (11): 3006-14. 10.1172/JCI29832.CrossRefPubMedPubMedCentral

20.

Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, Zhao H, Goto K, Peng LF, Chen WC, Chung RT: IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol. 2011, 55 (2): 289-98. 10.1016/j.jhep.2010.11.019.CrossRefPubMed

21.

Gondois-Rey F, Dental C, Halfon P, Baumert TF, Olive D, Hirsch I: Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS One. 2009, 4 (2): e4319-10.1371/journal.pone.0004319.CrossRefPubMedPubMedCentral

22.

Helbig KJ, Ruszkiewicz A, Semendric L, Harley HA, McColl SR, Beard MR: Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology. 2004, 39 (5): 1220-9. 10.1002/hep.20167.CrossRefPubMed

23.

Diegelmann J, Beigel F, Zitzmann K, Kaul A, Goke B, Auernhammer CJ, Bartenschlager R, Diepolder HM, Brand S: Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One. 2010, 5 (12): e15200-10.1371/journal.pone.0015200.CrossRefPubMedPubMedCentral

24.

Knapp S, Warshow U, Ho KM, Hegazy D, Little AM, Fowell A, Alexander G, Thursz M, Cramp M, Khakoo SI: A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology. 2011, 141 (1): 320-5. 10.1053/j.gastro.2011.04.005. 325CrossRefPubMedPubMedCentral

25.

Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K: Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 2009, 10 (8): 702-14. 10.1038/gene.2009.72.CrossRefPubMed

26.

Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP: In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nat Genet. 2003, 33 (4): 469-75. 10.1038/ng1124.CrossRefPubMed

27.

Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW: Allelic variation in human gene expression. Science. 2002, 297 (5584): 1143-10.1126/science.1072545.CrossRefPubMed

28.

Lo HS, Wang Z, Hu Y, Yang HH, Gere S, Buetow KH, Lee MP: Allelic variation in gene expression is common in the human genome. Genome Res. 2003, 13 (8): 1855-62.PubMedPubMedCentral

29.

Grievink H, Stowell KM: Allele-specific differences in ryanodine receptor 1 mRNA expression levels may contribute to phenotypic variability in malignant hyperthermia. Orphanet J Rare Dis. 2010, 5: 10-10.1186/1750-1172-5-10.CrossRefPubMedPubMedCentral

30.

Yan H, Dobbie Z, Gruber SB, Markowitz S, Romans K, Giardiello FM, Kinzler KW, Vogelstein B: Small changes in expression affect predisposition to tumorigenesis. Nat Genet. 2002, 30 (1): 25-6. 10.1038/ng799.CrossRefPubMed

31.

Frodsham AJ, Zhang L, Dumpis U, Taib NA, Best S, Durham A, Hennig BJ, Hellier S, Knapp S, Wright M, Chiaramonte M, Bell JI, Graves M, Whittle HC, Thomas HC, Thursz MR, Hill AV, Hennig BJ, Hellier S, Knapp S, Wright M, Chiaramonte M, Bell JI, Graves M, Whittle HC, Thomas HC, Thursz MR, Hill AV: Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc Natl Acad Sci U S A. 2006, 103 (24): 9148-53. 10.1073/pnas.0602800103.CrossRefPubMedPubMedCentral

32.

Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A, Abrignani S, Mondelli MU, Barnaba V: Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest. 2004, 113 (7): 963-72. 10.1172/JCI200420515.CrossRefPubMedPubMedCentral

33.

Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR: A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013, 45 (2): 164-71. 10.1038/ng.2521.CrossRefPubMedPubMedCentral

34.

Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, Duong FH, Gerlach T, Malinverni R, Moradpour D, Negro F, Müllhaupt B, Bochud PY: IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med. 2013, 210 (6): 1109-16. 10.1084/jem.20130012.CrossRefPubMedPubMedCentral

35.

McFarland AP, Horner SM, Jarret A, Joslyn RC, Bindewald E, Shapiro BA, Delker DA, Hagedorn CH, Carrington M, Gale M, Savan R: The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol. 2014, 15 (1): 72-9. 10.1038/ni.2758. doi: 10.1038/ni.2758. Epub 2013 Nov 17CrossRefPubMed

Title: Detection of allele specific differences in IFNL3 (IL28B)mRNA expression
Authors: Susanne Knapp
Naeem Meghjee
Sorcha Cassidy
Khaleel Jamil
Mark Thursz
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Medical Genetics / Issue 1/2014
Electronic ISSN: 1471-2350
DOI: https://doi.org/10.1186/s12881-014-0104-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Detection of allele specific differences in IFNL3 (IL28B)mRNA expression

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

Diagnosis of Noonan syndrome and related disorders using target next generation sequencing

Associations between interleukin-1 gene polymorphisms and sepsis risk: a meta-analysis

The relationship between diastolic blood pressure and coronary artery calcification is dependent on single nucleotide polymorphisms on chromosome 9p21.3

A recall-by-genotype study of CHRNA5-A3-B4genotype, cotinine and smoking topography: study protocol

Role of estrogen related receptor beta (ESRRB) in DFN35B hearing impairment and dental decay

Compound heterozygous mutations in glycyl-tRNA synthetase are a proposed cause of systemic mitochondrial disease